Cargando...
The Use of Bruton’s Tyrosine Kinase Inhibitors to Treat Allergic Disorders
PURPOSE OF REVIEW: Studies show that inhibitors of Bruton’s tyrosine kinase (BTKis), currently FDA-approved for the treatment of B cell malignancies, can prevent IgE-mediated reactions through broad inhibition of the FcεRI signaling pathway in human mast cells and basophils. This review will summari...
Gardado en:
| Publicado en: | Curr Treat Options Allergy |
|---|---|
| Autor Principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Springer International Publishing
2021
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8050815/ https://ncbi.nlm.nih.gov/pubmed/33880321 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40521-021-00286-y |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|